The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I, first-in-human study to evaluate the tolerability, pharmacokinetics and preliminary efficacy of HuMax-tissue factor-ADC (TF-ADC) in patients with solid tumors.
 
Ulrik Niels Lassen
Consulting or Advisory Role - Lilly; Novartis
Research Funding - Roche Pharma AG
Travel, Accommodations, Expenses - Roche Pharma AG
 
David S. Hong
No Relationships to Disclose
 
Nikolaos Diamantis
No Relationships to Disclose
 
Vivek Subbiah
No Relationships to Disclose
 
Rajiv Kumar
No Relationships to Disclose
 
Morten Sorensen
No Relationships to Disclose
 
Steen Lisby
Employment - Genmab
Stock and Other Ownership Interests - Genmab
 
Robert L. Coleman
Honoraria - NCCN
Consulting or Advisory Role - Clovis Oncology; Esperance Pharmaceuticals; Genentech/Roche
Research Funding - Amgen; Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Esperance Pharmaceuticals; Johnson & Johnson; Merrimack; OncoMed
Travel, Accommodations, Expenses - Amgen; Array BioPharma; AstraZeneca/MedImmune; Gradalis; Merck; Merrimack; Millennium
 
Johann Sebastian De Bono
Honoraria - Astellas Pharma; AstraZeneca; Genentech/Roche; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Genentech/Roche; Sanofi
Research Funding - Arno Therapeutics (Inst); AstraZeneca (Inst); Genentech (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)